Related Experiment Video

Updated: May 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins in heart failure: the paradox between large randomized clinical trials and real life

Paloma Gastelurrutia1, Josep Lupón, Marta de Antonio

  • 1Germans Trias i Pujol Health Research Institute, Badalona, Spain.

Mayo Clinic Proceedings
|June 9, 2012
PubMed

Insights

Statins significantly improve survival in heart failure (HF) patients, regardless of HF cause. This real-world study found statin use independently reduced mortality risk in both ischemic and nonischemic HF populations.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure (HF) is a complex syndrome with diverse etiologies.
  • The role of statins in HF prognosis, particularly in nonischemic cases, remains a subject of investigation.
  • Real-world data can offer insights into treatment effectiveness beyond randomized controlled trials.

Purpose of the Study:

  • To evaluate the association between statin use and patient outcomes in a real-life cohort of individuals with heart failure.
  • To specifically assess prognosis in patients with both ischemic and nonischemic heart failure etiologies.
  • To determine if statins offer a survival benefit irrespective of heart failure cause.

Main Methods:

  • Prospective study of 960 heart failure patients with preserved or depressed left ventricular ejection fraction (LVEF).
  • Patients were referred to a university hospital HF clinic and followed for up to 9.1 years.
  • Survival analysis was performed comparing statin users and non-users, adjusting for multiple prognostic factors.

Main Results:

  • Statin therapy was associated with a significant reduction in mortality risk (HR 0.45; P<.001).
  • This survival benefit persisted after adjusting for key prognostic factors including HF etiology and LVEF.
  • Statins demonstrated a significant association with lower mortality in both ischemic (P=.007) and nonischemic (P=.002) heart failure patients.

Conclusions:

  • In a real-world setting, statins are independently linked to improved survival in heart failure patients.
  • This association holds true even for patients with nonischemic heart failure etiology.
  • Findings contrast with some large randomized trials, highlighting the value of real-world evidence in HF management.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...